<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Recommended doses for selected agents to treat hypertensive infants</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Recommended doses for selected agents to treat hypertensive infants</h1>
<div class="graphic"><div class="figure"><div class="ttl">Recommended doses for selected agents to treat hypertensive infants</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="12%"></colgroup><colgroup width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Class</td> <td class="subtitle1">Drug</td> <td class="subtitle1">Route</td> <td class="subtitle1">Dose range</td> <td class="subtitle1">Interval</td> <td class="subtitle1">Comments</td> </tr> <tr> <td rowspan="4">ACE inhibitors</td> <td rowspan="2">Captopril</td> <td rowspan="2">Oral</td> <td> <p>&lt;3 months – 0.01 to 0.5 mg/kg/dose</p> Maximum 2 mg/kg/day</td> <td rowspan="2">3 to 4 times per day</td> <td rowspan="4"> <ol class="numbers_to_nine"> <li>First dose may cause rapid drop in BP, especially if receiving diuretics </li> <li>In infants already receiving a diuretic, start at the lowest recommended dose </li> <li>Monitor serum creatinine and potassium </li> <li>Intravenous enalaprilat is <strong>not</strong> recommended; see text </li> <li>Only captopril and enalapril are US Food and Drug Administration approved in infancy </li> <li>ACE inhibitors should not be used in infants who are less than 44 weeks postconceptual age </li> </ol> </td> </tr> <tr> <td> <p>&gt;3 months – 0.15 to 0.3 mg/kg/dose</p> Maximum 6 mg/kg/day</td> </tr> <tr> <td>Enalapril</td> <td>Oral</td> <td>0.08 to 0.6 mg/kg/day</td> <td>1 or 2 times per day</td> </tr> <tr> <td>Lisinopril</td> <td>Oral</td> <td>0.07 to 0.6 mg/kg/day</td> <td>1 time per day</td> </tr> <tr class="highlight_lght_gray_text"> <td rowspan="4">Alpha and beta antagonists</td> <td rowspan="3">Labetalol</td> <td>Oral</td> <td> <p>0.5 to 1 mg/kg/dose</p> Maximum 10 mg/kg/day</td> <td>2 or 3 times per day</td> <td rowspan="3">Acute decompensated heart failure, bronchopulmonary dysplasia-relative contraindications</td> </tr> <tr class="highlight_lght_gray_text"> <td>IV bolus</td> <td>0.2 to 1 mg/kg/dose</td> <td>Administer every 4 to 6 hours</td> </tr> <tr class="highlight_lght_gray_text"> <td>IV infusion</td> <td>0.25 to 3 mg/kg/hour</td> <td>Continuous infusion</td> </tr> <tr class="highlight_lght_gray_text"> <td>Carvedilol</td> <td>Oral</td> <td>0.1 mg/kg/dose up to 0.5 mg/kg/dose</td> <td>2 times per day</td> <td>May be useful in chronic heart failure</td> </tr> <tr> <td rowspan="2">Beta antagonists</td> <td>Esmolol</td> <td>IV infusion</td> <td>100 to 500 mcg/kg/minute</td> <td>Continuous infusion</td> <td> <p>Very short-acting; constant infusion necessary</p> May be useful for management of acute hypertension after repair of aortic coarctation</td> </tr> <tr> <td>Propranolol</td> <td>Oral</td> <td> <p>0.5 to 1 mg/kg/dose</p> Maximum 8 to 10 mg/kg/day</td> <td>3 to 4 times per day</td> <td>Monitor heart rate; avoid in bronchopulmonary dysplasia</td> </tr> <tr class="highlight_lght_gray_text"> <td rowspan="3">Calcium channel blockers</td> <td>Amlodipine</td> <td>Oral</td> <td> <p>0.05 to 0.3 mg/kg/dose</p> Maximum 0.6 mg/kg/day</td> <td>1 time per day</td> <td> <p>May cause mild reflex tachycardia</p> <p> Some infants may benefit by dividing dose twice per day</p> Full effect of dose adjustment may require 1 week or more</td> </tr> <tr class="highlight_lght_gray_text"> <td>Isradipine</td> <td>Oral</td> <td> <p>0.05 to 0.15 mg/kg/dose</p> Maximum 0.8 mg/kg/day</td> <td>4 times per day</td> <td rowspan="2">May cause mild reflex tachycardia</td> </tr> <tr class="highlight_lght_gray_text"> <td>Nicardipine</td> <td>IV infusion</td> <td>0.5 to 4 mcg/kg/minute</td> <td>Continuous infusion</td> </tr> <tr> <td>Central alpha agonist</td> <td>Clonidine</td> <td>Oral</td> <td> <p>5 to 10 mcg/kg/day</p> Maximum 25 mcg/kg/day</td> <td>Divided 2 to 4 times per day</td> <td>May cause mild sedation</td> </tr> <tr class="highlight_lght_gray_text"> <td rowspan="3">Diuretics</td> <td>Chlorothiazide</td> <td>Oral</td> <td>5 to 15 mg/kg/dose</td> <td>2 times per day</td> <td rowspan="3">Monitor electrolytes</td> </tr> <tr class="highlight_lght_gray_text"> <td>Hydrochlorothiazide</td> <td>Oral</td> <td>1 to 3 mg/kg/day</td> <td>1 time per day, or as 2 divided doses per day</td> </tr> <tr class="highlight_lght_gray_text"> <td>Spironolactone</td> <td>Oral</td> <td>0.5 to 1.5 mg/kg/dose</td> <td>2 times per day</td> </tr> <tr> <td rowspan="4">Vasodilators</td> <td rowspan="2">Hydralazine</td> <td>Oral</td> <td> <p>0.25 to 1 mg/kg/dose</p> Maximum 7.5 mg/kg/day</td> <td>3 to 4 times per day</td> <td rowspan="2">Tachycardia and fluid retention are common side effects</td> </tr> <tr> <td>IV bolus</td> <td>0.15 to 0.6 mg/kg/dose</td> <td>Q 4 hours</td> </tr> <tr> <td>Minoxidil</td> <td>Oral</td> <td>0.1 to 0.2 mg/kg/dose</td> <td>2 to 3 times per day</td> <td>Tachycardia and fluid retention common side effects; prolonged use causes hypertrichosis; pericardial effusion may occur</td> </tr> <tr> <td>Nitroprusside</td> <td>IV infusion</td> <td>0.5 to 10 mcg/kg/minute</td> <td>Continuous infusion</td> <td>Thiocyanate toxicity can occur with prolonged (&gt;72 hour) use or in renal failure</td> </tr> </tbody></table></div><div class="graphic_footnotes">ACE inhibitor: angiotensin-converting enzyme inhibitor; 
    BP: blood pressure; 
    IV: intravenous.</div><div class="graphic_reference">Adapted from: Dionne JM, Abitbol CL, Flynn JT. Hypertension in infancy: diagnosis, management, and outcome. Pediatr Nephrol 2011 with kind permission from Springer Science + Business Media B.V. Copyright © 2011.</div><div id="graphicVersion">Graphic 63077 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
